Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM

mAbs

Volumn 8, Issue 2, 2016, Pages 414-425

  Cho, Seulki ^a,b   Park, Insoo ^c,d   Kim, Haejung ^b   Jeong, Mun Sik ^b   Lim, Mooney ^b   Lee, Eung Suk ^b,e   Kim, Jin Hong ^b   Kim, Semi ^c   Hong, Hyo Jeong ^b  

^a University of Science and Technology (UST)   (South Korea)

^b Kangwon National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d National Cancer Center   (South Korea)

^e Scripps Korea Antibody Institute   (South Korea)

Author keywords

Affinity maturation; Cancer; Human monoclonal antibody; L1CAM; Phage display; Yeast display

Indexed keywords

AB 417; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; UNCLASSIFIED DRUG; CANCER ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BINDING AFFINITY; CROSS REACTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG SCREENING; GENETICS; HAMSTER; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PC12 CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEURAL CELL ADHESION MOLECULE L1; PC12 CELLS; RATS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964499494     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1125067     Document Type: Article

References (54)

1. HaspelJ, GrumetM.The L1CAM extracellular region: a multidomain protein with modular and cooperative binding modes. Front Biosci2003; 8:s1210-25; PMID:12957823; http://dx.doi.org/10.2741/1108
2. RathjenFG, SchachnerM.Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J1984; 3:1-10; PMID:6368220
3. PancookJD, ReisfeldRA, VarkiN, VitielloA, FoxRI, MontgomeryAM.Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J Immunol1997; 158:4413-21; PMID:9127006
4. DebiecH, ChristensenEI, RoncoPM.The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. J Cell Biol1998; 143:2067-79; PMID:9864376; http://dx.doi.org/10.1083/jcb.143.7.2067
5. ThorG, ProbstmeierR, SchachnerM.Characterization of the cell adhesion molecules L1, N-CAM and J1 in the mouse intestine. EMBO J1987; 6:2581-6; PMID:3315649
6. RavehS, GavertN, Ben-Ze’evA.L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett2009; 282:137-45; PMID:19144458; http://dx.doi.org/10.1016/j.canlet.2008.12.021
7. KiefelH, BondongS, Erbe-HoffmannN, HazinJ, RiedleS, WolfJ, PfeiferM, ArltA, SchäferH, MüerkÖsterSS, et al.L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene2010; 29:4766-78; PMID:20543863; http://dx.doi.org/10.1038/onc.2010.230
8. KiefelH, BondongS, PfeiferM, SchirmerU, Erbe-HoffmannN, SchäferH, SebensS, AltevogtP.EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kB activation. Carcinogenesis2012; 33:1919-29; PMID:22764136; http://dx.doi.org/10.1093/carcin/bgs220
9. HallH, WalshFS, DohertyP.Review: a role for the FGF receptor in the axonal growth response stimulated by cell adhesion molecules?Cell Adhes Commun1996; 3:441-50; PMID:8807188; http://dx.doi.org/10.3109/15419069609081021
10. DonierE, Gomez-SanchezJA, Grijota-MartinezC, LakomaJ, BaarsS, Garcia-AlonsoL, CabedoH.L1CAM binds ErbB receptors through Ig-like domains coupling cell adhesion and neuregulin signalling. PLoS One2012; 7:e40674; PMID:22815787; http://dx.doi.org/10.1371/journal.pone.0040674
11. GouveiaRM, GomesCM, SousaM, AlvesPM, CostaJ.Kinetic analysis of L1 homophilic interaction: role of the first four immunoglobulin domains and implications on binding mechanism. J Biol Chem2008; 283:28038-47; PMID:18701456; http://dx.doi.org/10.1074/jbc.M804991200
12. HaspelJ, FriedlanderDR, Ivgy-MayN, ChickramaneS, RoonprapuntC, ChenS, SchachnerM, GrumetM.Critical and optimal Ig domains for promotion of neurite outgrowth by L1/Ng-CAM. J Neurobiol2000; 42:287-302; PMID:10645969; http://dx.doi.org/10.1002/(SICI)1097-4695(20000215)42:3%3c287::AID-NEU1%3e3.0.CO;2-X
13. YipPM, ZhaoX, MontgomeryAM, SiuCH.The Arg-Gly-Asp motif in the cell adhesion molecule L1 promotes neurite outgrowth via interaction with the alphavbeta3 integrin. Mol Biol Cell1998; 9:277-90; PMID:9450954; http://dx.doi.org/10.1091/mbc.9.2.277
14. KulahinN, LiS, HinsbyA, KiselyovV, BerezinV, BockE.Fibronectin typeIII(FN3) modules of the neuronal cell adhesion molecule L1 interact directly with the fibroblast growth factor (FGF) receptor. Mol Cell Neurosci2008; 37:528-36; PMID:18222703; http://dx.doi.org/10.1016/j.mcn.2007.12.001
15. SillettiS, YebraM, PerezB, CirulliV, McMahonM, MontgomeryAM.Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem2004; 279:28880-8; PMID:15128735; http://dx.doi.org/10.1074/jbc.M404075200
16. GavertN, Conacci-SorrellM, GastD, SchneiderA, AltevogtP, BrabletzT, Ben-Ze’evA.L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol2005; 168:633-42; PMID:15716380; http://dx.doi.org/10.1083/jcb.200408051
17. ZecchiniS, BianchiM, ColomboN, FasaniR, GoisisG, CasadioC, VialeG, LiuJ, HerlynM, GodwinAK, et al.The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res2008; 68:1110-8; PMID:18281486; http://dx.doi.org/10.1158/0008-5472.CAN-07-2897
18. MinJK, KimJM, LiS, LeeJW, YoonH, RyuCJ, JeonSH, LeeJH, KimJY, YoonHK, et al.L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin Cancer Res2010; 16:3571-80; PMID:20501614; http://dx.doi.org/10.1158/1078-0432.CCR-09-3075
19. JungJ, SonYS, ParkH, JeonSK, LeeJW, ChoiSY, KimJM, KwonYG, HongHJ, MinJK.The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo. Oncol Rep2011; 25:945-52; PMID:21318226; http://dx.doi.org/10.3892/or.2011.1181
20. Sebens MuerkosterS, WerbingV, SiposB, DebusMA, WittM, GrossmannM, LeisnerD, KötteritzschJ, KappesH, KlöppelG, et al.Druginduced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene2007; 26:2759-68; PMID:17086212; http://dx.doi.org/10.1038/sj.onc.1210076
21. BenQ, AnW, FeiJ, XuM, LiG, LiZ, YuanY.Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells. Exp Ther Med2014; 7:785-90; PMID:24660028
22. YoonH, MinJK, LeeDG, KimDG, KohSS, HongHJ.L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett2012; 316:70-6; PMID:22088438; http://dx.doi.org/10.1016/j.canlet.2011.10.024
23. MagriniE, VillaA, AngioliniF, DoniA, MazzarolG, RudiniN, MaddalunoL, KomutaM, TopalB, PrenenH, et al.Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. J Clin Invest2014; 124:4335-50; PMID:25157817; http://dx.doi.org/10.1172/JCI70683
24. Grage-GriebenowE, JergE, GorysA, WickleinD, WeschD, Freitag-WolfS, GoebelL, VogelI, BeckerT, EbsenM, et al.L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol2014; 8:982-97; PMID:24746181; http://dx.doi.org/10.1016/j.molonc.2014.03.001
25. SlamonDJ, Leyland-JonesB, ShakS, FuchsH, PatonV, BajamondeA, FlemingT, EiermannW, WolterJ, PegramM, et al.Use of chemotherapy plus amonoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2. N Engl J Med2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
26. SmithIE.Trastuzumab for early breast cancer. Lancet2006; 367:107; PMID:16413866; http://dx.doi.org/10.1016/S0140-6736(06)67951-8
27. BaselgaJ, SwainSM.Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656
28. CunninghamD, HumbletY, SienaS, KhayatD, BleibergH, SantoroA, BetsD, MueserM, HarstrickA, VerslypeC, et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025
29. ArltMJ, Novak-HoferI, GastD, GschwendV, MoldenhauerG, GrunbergJ, HonerM, SchubigerPA, AltevogtP, KrügerA.Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res2006; 66:936-43; PMID:16424028; http://dx.doi.org/10.1158/0008-5472.CAN-05-1818
30. WolterinkS, MoldenhauerG, FogelM, KiefelH, PfeiferM, LuttgauS, GouveiaR, CostaJ, EndellJ, MoebiusU, et al.Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res2010; 70:2504-15; PMID:20215505; http://dx.doi.org/10.1158/0008-5472.CAN-09-3730
31. LeeES, JeongMS, SinghR, JungJ, YoonH, MinJK, KimKH, HongHJ.A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model. Exp Mol Med2012; 44:293-302; PMID:22248567; http://dx.doi.org/10.3858/emm. 2012.44.4.027
32. McCaffertyJ, GriffithsAD, WinterG, ChiswellDJ.Phage antibodies: filamentous phage displaying antibody variable domains. Nature1990; 348:552-4; PMID:2247164; http://dx.doi.org/10.1038/348552a0
33. WinterG, GriffithsAD, HawkinsRE, HoogenboomHR.Making antibodies by phage display technology. Annu Rev Immunol1994; 12:433-55; PMID:8011287; http://dx.doi.org/10.1146/annurev.iy.12.040194.002245
34. BoderET, WittrupKD.Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553
35. ZhouH, ZhangYL, LuG, JiH, RodiCP.Recombinant antibody libraries and selection technologies. N Biotechnol2011; 28:448-52; PMID:21477669; http://dx.doi.org/10.1016/j.nbt.2011.03.013
36. BradburyAR, SidhuS, DubelS, McCaffertyJ.Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol2011; 29:245-54; PMID:21390033; http://dx.doi.org/10.1038/nbt.1791
37. ChaoG, LauWL, HackelBJ, SazinskySL, LippowSM, WittrupKD.Isolating and engineering human antibodies using yeast surface display. Nat Protoc2006; 1:755-68; PMID:17406305; http://dx.doi.org/10.1038/nprot.2006.94
38. KhanSA, ThomasHC, DavidsonBR, Taylor-RobinsonSD.Cholangiocarcinoma. Lancet2005; 366:1303-14; PMID:16214602; http://dx. doi.org/10.1016/S0140-6736(05)67530-7
39. ValleJ, WasanH, PalmerDH, CunninghamD, AnthoneyA, MaraveyasA, MadhusudanS, IvesonT, HughesS, PereiraSP, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med2010; 362:1273-81; PMID:20375404; http://dx.doi.org/10.1056/NEJMoa0908721
40. RizviS, BoradMJ, PatelT, GoresGJ.Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis2014; 34:456-64; PMID:25369307; http://dx.doi.org/10.1055/s-0034-1394144
41. LiS, JoYS, LeeJH, MinJK, LeeES, ParkT, KimJM, HongHJ.L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res2009; 15:7345-51; PMID:19920102; http://dx.doi.org/10.1158/1078-0432.CCR-09-0959
42. ChoiSY, JoYS, HuangSM, LiangZL, MinJK, HongHJ, KimJM.L1 cell adhesion molecule as a novel independent poor prognostic factor in gallbladder carcinoma. Hum Pathol2011; 42:1476-83; PMID:21496863; http://dx.doi.org/10.1016/j.humpath.2011.01.003
43. WeiCH, LeeES, JeonJY, HeoYS, KimSJ, JeonYH, KimKH, HongHJ, RyuSE.Structural mechanism of the antigen recognition by the L1 cell adhesion molecule antibody A10-A3. FEBS Lett2011; 585:153-8; PMID:21094640; http://dx.doi.org/10.1016/j.febslet.2010.11.028
44. WeidleUH, EggleD, KlostermannS.L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res2009; 29:4919-31; PMID:20044598
45. MechtersheimerS, GutweinP, Agmon-LevinN, StoeckA, OleszewskiM, RiedleS, PostinaR, FahrenholzF, FogelM, LemmonV, et al.Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol2001; 155:661-73; PMID:11706054; http://dx.doi.org/10.1083/jcb.200101099
46. SchaferH, DieckmannC, KorniienkoO, MoldenhauerG, KiefelH, SalnikovA, KrügerA, AltevogtP, SebensS.Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett2012; 319:66-82; PMID:22210381; http://dx.doi.org/10.1016/j.canlet.2011.12.035
47. KiefelH, BondongS, HazinJ, RidingerJ, SchirmerU, RiedleS, AltevogtP.L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr2012; 6:374-84; PMID:22796939; http://dx.doi.org/10.4161/cam.20832
48. DonatoR, MiljanEA, HinesSJ, AouabdiS, PollockK, PatelS, EdwardsFA, SindenJD.Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci2007; 8:36; PMID:17531091; http://dx.doi.org/10.1186/1471-2202-8-36
49. UrlaubG, KasE, CarothersAM, ChasinLA.Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell1983; 33:405-12; PMID:6305508; http://dx.doi.org/10.1016/0092-8674(83)90422-1
50. JungE, LeeJ, HongHJ, ParkI, LeeY.RNA recognition by a human antibody against brain cytoplasmic 200 RNA. RNA2014; 20:805-14; PMID:24759090; http://dx.doi.org/10.1261/rna.040899.113
51. OhMS, KimKS, JangYK, MaengCY, MinSH, JangMH, YoonSO, KimJH, HongHJ.A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins. J Immunol Methods2003; 283:77-89; PMID:14659901; http://dx.doi.org/10.1016/j.jim.2003.08.010
52. CoomberDW.Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol2002; 178:133-45; PMID:11968482
53. YoonSO, LeeTS, KimSJ, JangMH, KangYJ, ParkJH, KimKS, LeeHS, RyuCJ, GonzalesNR, et al.Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem2006; 281:6985-92; PMID:16407221; http://dx.doi.org/10.1074/jbc. M511165200
54. LeeCV, LiangWC, DennisMS, EigenbrotC, SidhuSS, FuhG.High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051